By now, it’s clear: the alterations COVID-19 made to the life sciences landscape aren’t going away. Fortunately, some of those changes are largely positive: developments made during the pandemic have given rise to new investment opportunities and advanced drug development techniques. Now, the industry is facing a new world: one where partnerships are preferred, technology is the ticket to de-risking drug development, and supply chain disruptions could threaten the very lifeblood of life sciences.
 

The 2022 BDO Life Sciences CFO Outlook Survey polls life sciences industry CFOs to understand their plans to navigate this new world — and how they will shape the future of the industry.